Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis
Paul M. Derderian(The University of Texas MD Anderson Cancer Center), Michael Keating(The University of Texas MD Anderson Cancer Center), Sherry Pierce(The University of Texas MD Anderson Cancer Center), Elihu H. Estey(University of Washington), Moshe Talpaz(University of Michigan–Ann Arbor), H. Kantarjian(The University of Texas MD Anderson Cancer Center), Ann Cork(The University of Texas MD Anderson Cancer Center), Susan O’Brien(The University of Texas MD Anderson Cancer Center)
Cited by 111
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k